3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
Here's why Argenx could keep winning.
Argenx (ARGX) has experienced an impressive 180% increase in share price since early 2022, outperforming the S&P 500 by threefold. The company's unique position in biotechnology is attributed to its pipeline-in-a-product, efgartigimod alfa, which is marketed as Vyvgart and Vyvgart Hytrulo. Vyvgart is already approved for treating generalized myasthenia gravis (gMG) in the US and Japan, with an addressable market of around 28,000 patients.
The company is also seeking FDA approval for oMG, an indication with a larger patient population of at least 7,000. Argenx has ample financial resources, with $3.7 billion in cash and $1.3 billion in earnings for the first nine months of 2026. The company's strong operating margins and large cash reserves enable it to invest in pipeline development without issuing new shares.
With several promising candidates in its pipeline, such as empasibart for multifocal motor neuropathy and adimanebart for congenital myasthenic syndromes, Argenx is well-positioned for future growth. However, there are risks to consider, including clinical failure, valuation concerns, and the volatility associated with biotech stocks.
Despite these challenges, Wall Street analysts remain optimistic about Argenx's prospects, with 19 out of 20 recommending a buy rating.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
